NPM1 and acute myeloid leukemia: Selinexor has also been studied in combination with high-dose cytarabine and mitoxantrone in adult patients with newly diagnosed AML or with relapsed/refractory AML, in a phase 1 study, which included five (25%) patients with NPM1 mutations [58].